Evidence map›Paper›PMID 37124072›Full record

ArticleJAC-antimicrobial resistance2023

Association between minimum inhibitory concentration values and mortality risk in patients with

Sadia H Sarzynski, Alexander Lawandi, Sarah Warner, Cumhur Y Demirkale, Jeffrey R Strich, John P Dekker, Ahmed Babiker, Willy Li, Sameer S Kadri

Open access · goldAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in JAC-antimicrobial resistance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.8field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. What Drives Mortality inMicroorganisms · 2025
    Article
  2. A Mortality Prediction Nomogram forInfection and drug resistance · 2025
    Article
  3. Understanding the rationale and clinical impact of the revised CLSI 2024 minocycline susceptibility breakpoints against Stenotrophomonas maltophilia.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024
    Article
  4. Pathogens (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sadia H SarzynskiCritical Care Medicine Department, National Institutes of Health Clinical Center, 10 Center Drive B10, 2C145, Bethesda, MD 20892, USA.
Alexander LawandiCritical Care Medicine Department, National Institutes of Health Clinical Center, 10 Center Drive B10, 2C145, Bethesda, MD 20892, USA.ORCID https://orcid.org/0000-0001-7948-3161
Sarah WarnerCritical Care Medicine Department, National Institutes of Health Clinical Center, 10 Center Drive B10, 2C145, Bethesda, MD 20892, USA.
Cumhur Y DemirkaleCritical Care Medicine Department, National Institutes of Health Clinical Center, 10 Center Drive B10, 2C145, Bethesda, MD 20892, USA.
Jeffrey R StrichCritical Care Medicine Department, National Institutes of Health Clinical Center, 10 Center Drive B10, 2C145, Bethesda, MD 20892, USA.
John P DekkerBacterial Pathogenesis and Antimicrobial Resistance Unit, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.
Ahmed BabikerDivision of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA.ORCID https://orcid.org/0000-0003-0578-4871
Willy LiPharmacy Department, National Institutes of Health Clinical Center, Bethesda, MD, USA.
Sameer S KadriCritical Care Medicine Department, National Institutes of Health Clinical Center, 10 Center Drive B10, 2C145, Bethesda, MD 20892, USA.ORCID https://orcid.org/0000-0002-4420-9004
National Institutes of Health Clinical Center · USEmory University · USNational Institute of Allergy and Infectious Diseases · US

Funding

Application of Genomic Approaches to Bacterial Pathogenesis and Mechanisms of Antimicrobial ResistanceZIAAI001249 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI DEKKER, JOHN · 2019 to 2025
$13.7M
Big Data- Epidemiology of Antimicrobial ResistanceZIACL090046 · CLC · CLINICAL CENTER · PI KADRI, SAMEER · 2017 to 2025
$0k
6 · The paper itself

Abstract

Background: Clinical data informing antimicrobial susceptibility breakpoints for Methods: Inpatients with Results: Seventy-three of 851 levofloxacin-treated patients had levofloxacin MIC of exactly 2 mg/L (current Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoint) and served as the reference category for levofloxacin breakpoint models. In breakpoint model I ( Conclusions: In this retrospective study of real-world patients with

Identifiers

PMID37124072
PMCPMC10141776
OpenAlexW4367334890

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.